Multiple Myeloma

IRB #H-39242 / DFCI #19-291 (IxaPomDex): Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (temporary closure)

CIRB #H-39488/ SWOG S1803 (DRAMMATIC): Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

IRB #pend/ Yale Dara QOL: A Prospective, Observational Study of Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Relapsed or Refractory Multiple Myeloma (not yet submitted to IRB)